Skip to content
Surgical Oncology

Total Gastrectomy - Stomach Removal Surgery

About This Department

 
Surgical Oncology

Total gastrectomy, stomach removal surgery, takes out the whole stomach and joins the esophagus to the small bowel. Chemotherapy before and after the operation adds years to survival in stomach cancer.

Stomach cancer in the upper or middle stomach, or one that spreads through the whole wall, needs the entire stomach removed with its lymph nodes. In the MAGIC trial, five-year survival rose from 23 to 36 percent when chemotherapy came before and after surgery, and the FLOT4 trial raised median survival further, to 50 months. Life without a stomach means smaller meals and vitamin B12 for good. Send your endoscopy, biopsy and CT reports, and our team will tell you whether a total or a partial gastrectomy fits.

36% vs 23%
Five-year survival, chemotherapy around surgery against surgery alone, MAGIC trial
50 vs 35
Median survival in months, FLOT against older chemotherapy, 716 patients
65.3% vs 62.4%
Five-year survival, subtotal against total gastrectomy for lower stomach cancer
Free
Review of your reports before you book
Free consultation

A total gastrectomy removes the whole stomach, the fatty apron attached to it and the lymph nodes around its blood vessels. The surgeon then brings a loop of small bowel up to the esophagus, so food passes straight from the gullet into the bowel.

What the stomach does
The stomach stores a meal and releases it slowly, starts the digestion of protein, and makes intrinsic factor, the protein the body needs to absorb vitamin B12. After a total gastrectomy, the small bowel takes over the storage role in part, and vitamin B12 has to come by injection for life.
The authors believe that SG, which has been reported to be associated with a better nutritional status and quality of life, should be the procedure of choice, provided that the proximal margin of the resection falls in healthy tissue.
Italian randomized trial of 618 patients, Annals of Surgery, 1999
Total or subtotal
A subtotal gastrectomy removes the lower two thirds to four fifths of the stomach and keeps a small pouch at the top. It suits cancers in the lower stomach with enough healthy stomach above them. Whenever a subtotal operation clears the cancer, we choose it, since a stomach pouch makes eating easier.
Cancer in the upper or middle stomach
Too close to the top for a safe margin with a stomach pouch left behind.
Diffuse cancer
Signet ring cell cancer or linitis plastica spreading through the wall, where the edge of the tumor cannot be seen.
A hereditary CDH1 gene change
Risk-reducing removal of the whole stomach in carriers of hereditary diffuse gastric cancer.
Large tumors
Tumors spanning most of the stomach.

Total against subtotal gastrectomy

For lower stomach cancer, an Italian trial answered whether removing the whole stomach adds safety.

The Italian trial
Bozzetti and colleagues randomized 618 patients with cancer in the lower half of the stomach, with at least 6 cm of healthy stomach above the tumor, to subtotal or total gastrectomy during the operation. Five-year survival came out equal. Four patients died after subtotal and seven after total gastrectomy.

Five-year survival

The numbers side by side.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Italian trial, subtotal against total gastrectomy for lower stomach cancer, 618 patients
Outcome Subtotal Total
Survival at five years 65.3 percent 62.4 percent
Deaths after surgery 4 patients 7 patients
Verdict Equivalent Equivalent

Who needs a total gastrectomy

Adenocarcinoma of the upper or middle stomach accounts for the large majority. A smaller group carries an inherited change in the CDH1 gene.

Hereditary diffuse gastric cancer
CDH1 carriers face a high lifetime risk of a diffuse stomach cancer that endoscopy finds late. Removing the stomach before cancer appears, in the twenties or thirties, offers the most reliable protection, after genetic counseling and a careful talk about life without a stomach.

Chemotherapy before and after surgery

For any stomach cancer beyond the earliest stage, treatment starts with chemotherapy, and surgery follows. Staging comes first.

  1. Endoscopy with biopsy, including tests that guide drug choice.
  2. CT of the chest, abdomen and pelvis.
  3. Endoscopic ultrasound for depth of invasion.
  4. Diagnostic laparoscopy, to find spread on the lining of the abdomen that scans miss.
The MAGIC trial
Cunningham and colleagues randomized 503 patients to surgery alone or surgery with three cycles of chemotherapy before and three after. Five-year survival rose from 23 to 36 percent. Tumors came out smaller and less advanced at surgery, and complications after surgery matched, 46 against 45 percent, so the chemotherapy before the operation made it no more dangerous.

Four cycles of FLOT
One day of infusion every two weeks, four times, over eight weeks, given here or by your oncologist at home.
Restaging
A new CT.
Surgery
Four to six weeks after the last cycle, once blood counts and energy have recovered enough for a major operation.
Four more cycles
Once you have recovered from surgery.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Chemotherapy around surgery for stomach cancer, two randomized trials
Trial Comparison Result
MAGIC, 503 patients ECF chemotherapy with surgery against surgery alone Five-year survival 36 against 23 percent
FLOT4, 716 patients FLOT against ECF or ECX chemotherapy, both with surgery Median survival 50 against 35 months

The operation

Under general anesthesia, by keyhole or open surgery, the surgeon divides the stomach from the esophagus above and the duodenum below, removes it with its lymph nodes, and joins a Roux loop of small bowel to the esophagus with a circular stapler. The operation takes four to six hours. A feeding tube into the bowel goes in for some patients, to support nutrition in the first weeks. Then intensive care for the first night. Every specimen goes to the pathologist, who counts the lymph nodes and checks the margins, and that report decides the chemotherapy after surgery.


Lymph node removal

Stomach cancer spreads first to the lymph nodes along the stomach and its arteries. A D1 operation removes the nodes next to the stomach, a D2 operation also those along the main arteries behind it.


The Dutch D1D2 trial
Songun and colleagues randomized 1,078 patients across 80 Dutch hospitals and followed them for 15 years. D2 surgery cut local recurrence from 22 to 12 percent and deaths from stomach cancer from 48 to 37 percent, at the cost of higher operative mortality, 10 against 4 percent, when it often included removing the spleen and pancreatic tail.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Dutch D1D2 trial, 711 patients operated with curative intent, 15 years
Outcome D1 D2
Survival at 15 years 21 percent 29 percent, difference short of significance
Death from stomach cancer 48 percent 37 percent
Local recurrence 22 percent 12 percent
Deaths after surgery 4 percent 10 percent
Complications 25 percent 43 percent
D2 surgery today
The excess deaths in the D2 group came largely from removal of the spleen and pancreatic tail, now abandoned. Modern D2 surgery keeps both, and our surgeons perform it as the standard for stomach cancer.
After a median follow-up of 15 years, D2 lymphadenectomy is associated with lower locoregional recurrence and gastric-cancer-related death rates than D1 surgery.
Dutch D1D2 trial, Lancet Oncology, 2010

Keyhole surgery, recovery and life without a stomach

Keyhole total gastrectomy means five or six small incisions and a short one for the specimen.

The CLASS02 trial
Liu and colleagues randomized 227 patients with stage I stomach cancer to keyhole or open total gastrectomy in Chinese centers. Complications after surgery reached 18.1 percent after keyhole and 17.4 percent after open surgery, with no significant difference. The trial covered early cancers only.

  • A leak from the join between esophagus and bowel.
  • Bleeding.
  • Infection in the abdomen or chest.
  • A leak of pancreatic fluid after lymph node removal.
  • Blood clots, lowered by early walking and blood thinner injections.
The results of the CLASS02 trial showed that the safety of LTG with lymphadenectomy by experienced surgeons for clinical stage I gastric cancer was comparable to that of OTG.
CLASS02 trial, JAMA Oncology, 2020
Before you eat
A contrast X-ray or a careful clinical check confirms the join holds, and sips of water start on the second to fourth day, building up to soft food over the first week.
Eating without a stomach
Six small meals a day instead of three, protein at every meal, and drinks between meals instead of with them. Most patients lose 10 to 15 percent of their body weight in the first months and then hold steady.

Vitamins and blood

Lifelong supplements
Vitamin B12 injections every one to three months for life, since the body can no longer absorb it from food. Iron, calcium and vitamin D tablets, with blood tests every six to twelve months.

Dumping syndrome


Weight and diet

Dumping and how to avoid it
Food reaching the bowel too fast causes cramps, sweating and a racing heart within half an hour of eating, or weakness two to three hours later. Smaller meals, fewer sweet foods and more protein and fiber prevent it in most patients, and our dietitian plans the first months with you.

The first months


Results of chemotherapy around surgery

The FLOT4 trial
Al-Batran and colleagues randomized 716 patients in 38 German hospitals to FLOT or the older ECF or ECX chemotherapy, both given before and after surgery. Median survival reached 50 months with FLOT against 35 months, with the same rate of serious side effects, 27 percent in each group.
In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival.
MAGIC trial, New England Journal of Medicine, 2006

Risks in numbers and the stay in Istanbul

The stay in Istanbul
Plan seven to ten nights in hospital and two to three weeks in Istanbul in all, with our dietitian building up your meals before you leave. Our surgeon confirms fitness to fly once you eat and drink well and the wound has healed. A companion can sleep in your room. Our coordinators speak English, Arabic, French, Russian, Serbian, Romanian and Spanish, and follow-up after you return home runs through them, with the pathology report and the plan for chemotherapy after surgery sent to your oncologist. The cost depends on keyhole or open surgery, chemotherapy given here and the length of stay, and the estimate after the free review lists each.
The D2 procedure was also associated with significantly higher postoperative mortality, morbidity, and reoperation rates.
Dutch D1D2 trial, Lancet Oncology, 2010

Total gastrectomy FAQ

Can you live a normal life without a stomach?
Yes. Eating changes to small, frequent meals, and vitamin B12 comes by injection for life.
How much weight will I lose after a total gastrectomy?
Most patients lose 10 to 15 percent of their body weight in the first months and then hold steady.
Do I need chemotherapy before stomach removal surgery?
For cancers beyond the earliest stage, yes. Trials show longer survival with chemotherapy before and after surgery.
Can a total gastrectomy be done by keyhole surgery?
Yes, in experienced hands. The CLASS02 trial found the same complication rate as open surgery for early cancers.
How long is the hospital stay?
Seven to ten nights, then one to two more weeks in Istanbul.

References

  1. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Annals of Surgery. 1999;230(2):170-178.
  2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine. 2006;355(1):11-20.
  3. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957.
  4. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncology. 2010;11(5):439-449.
  5. Liu F, Huang C, Xu Z, et al. Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage I gastric cancer: the CLASS02 multicenter randomized clinical trial. JAMA Oncology. 2020;6(10):1590-1597.

Editor's note

Written by the Biruni Hospital medical editorial team. Reviewed by Prof. Dr. Özcan YILDIZ, Medical Oncology.

Last updated:

Related Treatments

View All